| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
144,332 |
103,090 |
$16.70M |
| D0999 |
Unspecified diagnostic procedure, by report |
693 |
539 |
$68K |
| 0011A |
|
302 |
293 |
$12K |
| 0012A |
|
270 |
264 |
$11K |
| 0001A |
|
132 |
130 |
$6K |
| 90651 |
|
956 |
836 |
$5K |
| 0002A |
|
89 |
88 |
$4K |
| 0054A |
|
90 |
90 |
$4K |
| 0064A |
|
86 |
84 |
$3K |
| 90734 |
|
1,153 |
1,037 |
$3K |
| 90670 |
|
2,576 |
2,202 |
$2K |
| 90633 |
|
1,973 |
1,744 |
$1K |
| 90834 |
Psychotherapy, 45 minutes with patient |
3,028 |
1,818 |
$1K |
| 0134A |
|
38 |
29 |
$1K |
| 90710 |
|
916 |
831 |
$1K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
3,494 |
2,961 |
$671.27 |
| 90715 |
|
846 |
769 |
$629.14 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
82,379 |
62,606 |
$492.25 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
15,396 |
12,618 |
$455.47 |
| G2012 |
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion |
28 |
20 |
$342.94 |
| 90832 |
Psychotherapy, 30 minutes with patient |
1,650 |
948 |
$331.65 |
| 90837 |
Psychotherapy, 53 minutes with patient |
879 |
590 |
$300.18 |
| 90686 |
|
2,096 |
1,796 |
$203.44 |
| 90698 |
|
736 |
631 |
$188.72 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
1,386 |
1,238 |
$176.77 |
| 90716 |
|
85 |
70 |
$142.10 |
| 90696 |
|
509 |
447 |
$123.03 |
| 90681 |
|
213 |
195 |
$117.45 |
| 90700 |
|
218 |
195 |
$106.15 |
| 90680 |
|
570 |
522 |
$82.89 |
| 90707 |
|
14 |
12 |
$77.32 |
| 90723 |
|
977 |
894 |
$76.95 |
| 90677 |
|
189 |
176 |
$59.61 |
| 90647 |
|
858 |
771 |
$58.86 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,081 |
971 |
$41.60 |
| Q3014 |
Telehealth originating site facility fee |
471 |
349 |
$25.00 |
| 81003 |
|
3,115 |
2,693 |
$2.18 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
10,501 |
8,642 |
$1.40 |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
147 |
145 |
$0.00 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
4,811 |
4,083 |
$0.00 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
4,009 |
3,513 |
$0.00 |
| 81025 |
|
3,087 |
2,460 |
$0.00 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
3,362 |
2,550 |
$0.00 |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
2,898 |
2,513 |
$0.00 |
| 80061 |
Lipid panel |
2,836 |
2,488 |
$0.00 |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
4,070 |
3,599 |
$0.00 |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
2,280 |
2,080 |
$0.00 |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
3,188 |
2,903 |
$0.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
732 |
631 |
$0.00 |
| 83540 |
|
241 |
224 |
$0.00 |
| 90791 |
Psychiatric diagnostic evaluation |
229 |
196 |
$0.00 |
| 99173 |
|
4,156 |
3,736 |
$0.00 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,633 |
1,002 |
$0.00 |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
211 |
207 |
$0.00 |
| 3077F |
|
187 |
168 |
$0.00 |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
68 |
67 |
$0.00 |
| 3078F |
|
673 |
595 |
$0.00 |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
368 |
342 |
$0.00 |
| 99382 |
|
59 |
59 |
$0.00 |
| 80321 |
|
280 |
161 |
$0.00 |
| 83655 |
|
524 |
443 |
$0.00 |
| 87512 |
|
30 |
28 |
$0.00 |
| 85014 |
|
13 |
13 |
$0.00 |
| 82570 |
|
83 |
78 |
$0.00 |
| 86038 |
|
16 |
16 |
$0.00 |
| 87481 |
|
15 |
13 |
$0.00 |
| 80348 |
|
28 |
26 |
$0.00 |
| D1120 |
Prophylaxis - child |
31 |
31 |
$0.00 |
| 99201 |
|
384 |
285 |
$0.00 |
| D0330 |
Panoramic radiographic image |
28 |
28 |
$0.00 |
| 90648 |
|
44 |
43 |
$0.00 |
| D0220 |
Intraoral - periapical first radiographic image |
20 |
12 |
$0.00 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
16 |
13 |
$0.00 |
| 87799 |
|
30 |
28 |
$0.00 |
| 87186 |
|
12 |
12 |
$0.00 |
| 80346 |
|
37 |
19 |
$0.00 |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
16 |
16 |
$0.00 |
| 80053 |
Comprehensive metabolic panel |
6,098 |
5,226 |
$0.00 |
| 87081 |
|
164 |
158 |
$0.00 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
946 |
825 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
7,128 |
6,269 |
$0.00 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
6,573 |
5,581 |
$0.00 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,389 |
2,108 |
$0.00 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,521 |
1,362 |
$0.00 |
| 84443 |
Thyroid stimulating hormone (TSH) |
3,492 |
2,988 |
$0.00 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
25 |
24 |
$0.00 |
| 81001 |
|
525 |
465 |
$0.00 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,139 |
2,624 |
$0.00 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
850 |
671 |
$0.00 |
| 83550 |
|
221 |
206 |
$0.00 |
| 82607 |
|
399 |
360 |
$0.00 |
| 84436 |
|
291 |
258 |
$0.00 |
| 3074F |
|
675 |
596 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
8,592 |
7,452 |
$0.00 |
| 90474 |
|
688 |
625 |
$0.00 |
| D0150 |
Comprehensive oral evaluation - new or established patient |
161 |
160 |
$0.00 |
| 82728 |
|
244 |
230 |
$0.00 |
| 82043 |
|
86 |
81 |
$0.00 |
| 87428 |
|
7,159 |
6,486 |
$0.00 |
| 82746 |
|
367 |
330 |
$0.00 |
| 99381 |
|
327 |
310 |
$0.00 |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
187 |
168 |
$0.00 |
| 87070 |
|
362 |
336 |
$0.00 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
703 |
606 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
5,510 |
4,843 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
329 |
284 |
$0.00 |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
128 |
126 |
$0.00 |
| 83735 |
|
421 |
380 |
$0.00 |
| 87807 |
|
818 |
710 |
$0.00 |
| 87430 |
|
607 |
584 |
$0.00 |
| 90744 |
|
39 |
38 |
$0.00 |
| 99383 |
|
148 |
140 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
83 |
80 |
$0.00 |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
112 |
95 |
$0.00 |
| 86592 |
|
44 |
35 |
$0.00 |
| 96127 |
|
153 |
145 |
$0.00 |
| 84479 |
|
268 |
239 |
$0.00 |
| 93000 |
|
69 |
64 |
$0.00 |
| 99384 |
|
57 |
52 |
$0.00 |
| 36416 |
|
53 |
49 |
$0.00 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
57 |
52 |
$0.00 |
| 3080F |
|
185 |
167 |
$0.00 |
| 86580 |
|
26 |
25 |
$0.00 |
| 87088 |
|
96 |
66 |
$0.00 |
| D1206 |
Topical application of fluoride varnish |
50 |
50 |
$0.00 |
| 84153 |
|
29 |
29 |
$0.00 |
| 85018 |
|
14 |
14 |
$0.00 |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
68 |
48 |
$0.00 |
| 80349 |
|
70 |
44 |
$0.00 |
| D0140 |
Limited oral evaluation - problem focused |
27 |
16 |
$0.00 |